Skip to main content

CytRx Expands RNAi Collaboration with U Mass Med School

NEW YORK, April 30 - CytRx of Los Angeles said today that it has expanded its collaboration with University of Massachusetts Medical School, signing an sponsored-research agreement as the first phases of a drug-development effort in obesity and type II diabetes.

 

Michael Czech, chairman of the molecular medicine, will head the research effort that will apply RNAi-directed gene silencing to fat cells for target validation.

 

In early April, CytRx announced that it had signed a license agreement with UMMS for its proprietary portfolio of applications for RNAi-based gene silencing technology in obesity, type 2 diabetes, and cancer.

 

Interested in more on RNAi? Read GenomeWeb's weekly roundup of activity.

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.